Stay updated on First-Line Atezolizumab Combos in Head and Neck Clinical Trial

Sign up to get notified when there's something new on the First-Line Atezolizumab Combos in Head and Neck Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the First-Line Atezolizumab Combos in Head and Neck Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy evaluation of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:03.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals with histologically or cytologically confirmed recurrent/metastatic SCCHN that is considered incurable. Previously, no specific information was provided about the participation criteria.
    Difference
    16%
    Check dated 2024-05-22T21:34:06.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:18:26.000Z thumbnail image

Stay in the know with updates to First-Line Atezolizumab Combos in Head and Neck Clinical Trial

Enter your email address, and we'll notify you when there's something new on the First-Line Atezolizumab Combos in Head and Neck Clinical Trial page.